Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Xu, Cheng ^a   Wang, Huijun ^b   He, Hongyu ^c   Zheng, Fengyun ^c   Chen, Yating ^c   Zhang, Jin ^c   Lin, Xiaoyan ^a   Ma, Duan ^c   Zhang, Hongwei ^c  

^a TONGJI UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Immunohistochemical staining; Prognosis; Survival analysis; TFPI 2

Indexed keywords

PLACENTA PROTEIN 5;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR VOLUME; VESSEL INVASION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84874941057     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-118     Document Type: Article

References (33)

1. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009, 373(9673):1463-1479. 10.1016/S0140-6736(09)60316-0, 19394537.
2. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast cancer research: BCR 2000, 2(4):252-257. 10.1186/bcr65, 138784, 11250717.
3. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395-406. 10.1083/jcb.201102147, 3283993, 22351925.
4. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009, 9:188. 10.1186/1471-2407-9-188, 2706257, 19531263.
5. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004, 296(2):151-162. 10.1016/j.yexcr.2004.02.022, 15149846.
6. Schneider J, Pollan M, Tejerina A, Sanchez J, Lucas AR. Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer 2003, 88(1):96-101. 10.1038/sj.bjc.6600656, 2376772, 12556966.
7. Jandial V, Horne CH, Glover RG, Nisbet AD, Campbell DM, MacGillivray I. The value of measurement of pregnancy-specific proteins in twin pregnancies. Acta Genet Med Gemellol 1979, 28(4):319-325.
8. Liu Y, Stack SM, Lakka SS, Khan AJ, Woodley DT, Rao JS, Rao CN. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch Biochem Biophys 1999, 370(1):112-118. 10.1006/abbi.1999.1371, 10496984.
9. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996, 35(1):266-272. 10.1021/bi951501d, 8555184.
10. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schonbeck U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001, 107(9):1117-1126. 10.1172/JCI10403, 209273, 11342575.
11. Jin M, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I, Miyagi Y. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 2001, 83(2):325-333. 10.1006/gyno.2001.6394, 11606093.
12. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S, Rao JS. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clinical cancer research: an official journal of the American Association for Cancer Research 2001, 7(3):570-576.
13. Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001, 18(1):127-131.
14. Konduri SD, Tasiou A, Chandrasekar N, Nicolson GL, Rao JS. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000, 18(4):303-308. 10.1023/A:1011085820250, 11448060.
15. Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, Kisiel W, Woodley DT. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. International journal of cancer Journal international du cancer 1998, 76(5):749-756. 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y, 9610735.
16. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, Goggins M. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005, 24(5):850-858. 10.1038/sj.onc.1208050, 15592528.
17. Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q, Ma D. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 2007, 8:110. 10.1186/1471-2199-8-110, 2233638, 18053161.
18. Takada H, Wakabayashi N, Dohi O, Yasui K, Sakakura C, Mitsufuji S, Taniwaki M, Yoshikawa T. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet Cytogenet 2010, 197(1):16-24. 10.1016/j.cancergencyto.2009.11.004, 20113832.
19. Rollin J, Iochmann S, Blechet C, Hube F, Regina S, Guyetant S, Lemarie E, Reverdiau P, Gruel Y. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005, 92(4):775-783. 10.1038/sj.bjc.6602298, 2361876, 15685245.
20. Vaitkiene P, Skiriute D, Skauminas K, Tamasauskas A. Associations between TFPI-2 methylation and poor prognosis in glioblastomas. Medicina (Kaunas) 2012, 48(7):345-349.
21. Tsuda H. Individualization of breast cancer based on histopathological features and molecular alterations. Breast Cancer 2008, 15(2):121-132. 10.1007/s12282-008-0032-5, 18320292.
22. Kong D, Ma D, Bai H, Guo H, Cai X, Mo W, Tang Q, Song H. Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2. Biochem Biophys Res Commun 2004, 324(4):1179-1185. 10.1016/j.bbrc.2004.09.179, 15504338.
23. Kim Y, Stolarska MA, Othmer HG. The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol 2011, 106(2):353-379. 10.1016/j.pbiomolbio.2011.06.006, 3156881, 21736894.
24. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. Breast cancer research: BCR 2004, 6(2):93-101. 10.1186/bcr772, 400664, 14979914.
25. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:20. 10.1186/1471-2407-9-20, 2631003, 19144199.
26. Sliutz G, Eder H, Koelbl H, Tempfer C, Auerbach L, Schneeberger C, Kainz C, Zeillinger R. Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. Breast Cancer Res Treat 1996, 40(3):257-263. 10.1007/BF01806814, 8883968.
27. Rabbani SA, Xing RH. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 1998, 12(4):911-920.
28. Stillfried GE, Saunders DN, Ranson M. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast cancer research: BCR 2007, 9(1):R14. 10.1186/bcr1647, 1851380, 17257442.
29. Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun 1999, 255(1):94-98. 10.1006/bbrc.1999.0153, 10082661.
30. Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, Brodie S, Kisiel W. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004, 103(3):1069-1077.
31. Xu Z, Maiti D, Kisiel W, Duh EJ. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26(12):2819-2825. 10.1161/01.ATV.0000248731.55781.87, 17023682.
32. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 2007, 27(2):310-316.
33. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002, 347(20):1593-1603. 10.1056/NEJMra021902, 12432047.